cp-55,940 has been researched along with Neuralgia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Astruc-Diaz, F; Brown, DL; Diaz, P; Naguib, M; Pan, HM; Xu, J | 1 |
| Adam, JM; Baker, J; Boyce, S; Campbell, R; Clark, JK; Cottney, JE; Davies, K; Deehan, M; Everett, K; Fields, R; Francis, S; Jeremiah, F; Kiyoi, T; Maidment, M; Martin, I; Morrison, A; Prosser, A; Ratcliffe, P; Schulz, J; Wishart, G | 1 |
| Barth, F; Cavasotto, CN; Chen, SR; Diaz, F; Diaz, P; Knight, L; Mackie, K; McDaniel, SW; Pan, HL; Petrov, RR; Wager-Miller, J | 1 |
3 other study(ies) available for cp-55,940 and Neuralgia
| Article | Year |
|---|---|
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Drug Design; Humans; Hydrazones; Isatin; Neuralgia; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; X-Ray Diffraction | 2008 |
Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Topics: Animals; Brain; Caco-2 Cells; Drug Design; Humans; Indoles; Mice; Neuralgia; Oxadiazoles; Rats; Receptor, Cannabinoid, CB1 | 2012 |
Mastering tricyclic ring systems for desirable functional cannabinoid activity.
Topics: Animals; Carbazoles; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuralgia; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2013 |